The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Type: Expression of concern
Notice date: 7/1/2019 0:00
Journal: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Publisher: American Association for Cancer Research
Notice DOI: 10.1158/1078-0432.ccr-19-1601
Original paper DOI: 10.1158/1078-0432.ccr-09-3022

Reasons